PRRUF Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EDT
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.03 - $0.33
Previous CloseN/A
Volume11.25K
Average Volume (3M)1.01K
Market Cap
$58.86M
Enterprise Value$10.28
Total Cash (Recent Filing)$68.87M
Total Debt (Recent Filing)$1.05M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Feb 25, 2027EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding1,473,721,300
10 Day Avg. Volume0
30 Day Avg. Volume1,010
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.27
Price to Sales (P/S)5.36
P/FCF Ratio-1.40
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$0.05Price Target Upside24.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$2.75M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthFY2026 revenue growth of about 144% indicates substantially stronger commercial traction than the prior year. If sustained, this expanding top line can improve operating leverage and provide a broader base for advancing the company’s clinical pipeline.
Gross Margin RecoveryThe roughly 83% FY2026 gross margin is a meaningful rebound from negative gross-profit profiles in several earlier years. A stronger gross-profit contribution could support future funding of clinical development, although it has not yet translated into company-wide profitability.
Low LeverageDebt of about $1.0M and debt-to-equity near 0.02 limit interest burden and balance-sheet leverage. Positive equity of roughly $61.5M still provides a capital buffer, giving Immutep more flexibility than a heavily indebted clinical-stage peer.
Bears Say
Persistent Net LossesFY2026 net loss of about $79.3M, alongside deeply negative operating and net margins, shows that operating expenses remain far above the company’s revenue base. Continued losses could delay self-funding and make sustainable earnings dependent on future execution.
Sustained Cash BurnOperating cash flow was about negative $55.5M and free cash flow about negative $55.6M in FY2026, with cash generation negative in every year shown. This sustained burn means Immutep remains cash consumptive and may need external funding before operating scale improves.
Equity ErosionEquity declined from about $143.6M in FY2025 to roughly $61.5M in FY2026, while returns on equity were strongly negative. This erosion reduces the capital buffer and signals funding or dilution risk if losses and cash consumption persist.
Immutep Ltd News
PRRUF FAQ
What was Immutep Ltd’s price range in the past 12 months?
Immutep Ltd lowest stock price was $0.03 and its highest was $0.33 in the past 12 months.
What is Immutep Ltd’s market cap?
Immutep Ltd’s market cap is $58.86M.
When is Immutep Ltd’s upcoming earnings report date?
Immutep Ltd’s upcoming earnings report date is Feb 25, 2027 which is in 163 days.
How were Immutep Ltd’s earnings last quarter?
Immutep Ltd released its earnings results on Sep 02, 2026. The company reported -$0.016 earnings per share for the quarter, missing the consensus estimate of -$0.003 by -$0.014.
Is Immutep Ltd overvalued?
According to Wall Street analysts Immutep Ltd’s price is currently Undervalued.
Does Immutep Ltd pay dividends?
Immutep Ltd does not currently pay dividends.
What is Immutep Ltd’s EPS estimate?
Immutep Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immutep Ltd have?
Immutep Ltd has 1,473,721,300 shares outstanding.
What happened to Immutep Ltd’s price movement after its last earnings report?
Immutep Ltd reported an EPS of -$0.016 in its last earnings report, missing expectations of -$0.003. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immutep Ltd?
Currently, no hedge funds are holding shares in PRRUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.05 (24.82% Upside)
$0.05 (24.82% Upside)
Blogger Sentiment
Bullish
PRRUF Sentiment 100%
Sector Average 62%
Sector Average 62%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
PRRUF Stock 12 Month Forecast
Average Price Target
$0.05
▲(24.82% Upside)
Technical Analysis
Imugene
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Radiopharm Theranostics Limited
―
Ownership Overview
2.21% Insiders
0.08% Mutual Funds
― Other Institutional Investors
97.71% Public Companies and
Individual Investors